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ABSTRACT 
 
The present study was designed to reveal the hitherto unknown efficacy of two commonly 
used hepatoprotective drugs, L-ornithine-L-aspartate (lornit) and silymarin in the regulation of 
kidney toxicity and thyroid dysfunction in mice. Renal and hepatic lipid peroxidation (LPO) 
was induced by the administration of carbon tetrachloride (CCl4) for 2 weeks (2.0 gm/kg 
twice a week). In two separate groups, along with CCl4 animals were also treated with either 
lornit (200 mg/kg) or silymarin (100 mg/kg) every day for the same duration. Other than he-
patic and renal LPO, alterations in the concentrations of serum triiodothyronine (T3), thyrox-
ine (T4), glucose and insulin and in hepatic type-1 iodothyronine 5’monodeiodinase (5’DI) 
activity were considered as major parameters. Simultaneously activities of serum aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphahatase (ALP) and 
hepatic and renal superoxide dismutase (SOD), catalase (CAT) and reduced glutathione con-
tent (GSH) were also studied. Lornit or silymarin administration reversed almost all the toxic 
effects exhibited by CCl4 including enhanced tissue LPO, serum ALT, AST and ALP activi-
ties and the concentrations of insulin and glucose. Both test drugs also significantly increased 
hepatic 5’DI activity, cellular antioxidants such as SOD, CAT and GSH and serum levels of 
both the thyroid hormones.  
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INTRODUCTION 
Liver dysfunction is a clinically relevant 
problem, which accounts a major popula-
tion of all the reported cases of acute liver 
failure (Lee, 2003; Yamazaki et al., 2005). 
Therefore very often hepatoprotective drugs 
are recommended to ameliorate liver prob-
lems. L-ornithine-L-aspartate (lornit) and 
silymarin are two such commonly used 
hepatoprotective drugs which are claimed 
to be highly effective against chemical-
induced toxicity (Maneesh and Jayalek-
shmi, 2005; Mansour et al., 2006; Poo et 
al., 2006; Upadhyay et al., 2007; Balderas-
Renteria et al., 2007; Jain et al., 2008). Al-
though these two drugs have been reported 
to provide hepatic protection (Vogels et al., 
1997; Rose et al., 1999), their potential to 
regulate kidney toxicity and thyroid dys-
function, if any, was yet to be established. 
Therefore, in the present investigation an 
attempt was made to reveal the relative ef-
ficacy of these two drugs to regulate kidney 
toxicity induced by carbon tetrachloride 
(CCl4). In fact, this drug has been used tra-
ditionally in rodent models to investigate 
the therapeutic interventions of hepatopro-
tective drugs (Paquet and Kamphausen, 
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1975; Clawson, 1989; Weber et al., 2003; 
He et al., 2006; Balderas-Renteria et al., 
2007). Toxicity generated from its reactive 
metabolite involves induction of oxidative 
stress on tissues (Perez Tamayo, 1983; 
Clawson, 1989; Weber et al., 2003; He et 
al., 2006) that causes liver injury and in-
variably alters hepatobiliary functions and 
very often results in impairment of hormo-
nal metabolism (Goel et al., 1994). 
Despite the fact that most biologically 
active thyroid hormone, triiodothyronine 
(T3) is largely produced in liver by the 
process of mono-deiodination of thyroxine 
(T4) with the help of the enzyme type-1 io-
dothyronine 5’-mondeiodinase (5’DI, 
Ganong, 2005) and there is every possibil-
ity of alteration in thyroid hormones in 
chemical-induced hepatotoxicity, nothing 
has been reported so far on the effects of 
hepatoprotective drugs on the alteration of 
thyroid function. 
In literature, lornit has already been re-
ported to ameliorate acute liver failure 
(Rose et al., 1999; Vogels et al., 1997), 
CCl4-induced liver damage (Gebhardt et al., 
1997), and hepatic encephalopathy (Kirch-
eis et al., 2002; Delcker et al., 2002). Simi-
larly, the hepatoprotective role of silymarin 
on CCl4-induced liver damage has also 
been investigated earlier (Balderas-Renteria 
et al., 2007; Jain et al., 2008). However, to 
the best of our knowledge no report is 
available till date on the impact of lornit or 
silymarin on renal oxidative stress and thy-
roid metabolism; although thyroid hor-
mones regulate almost all body functions 
(Ganong, 2005) and chronic medication 
with some drugs may result in altered levels 
of thyroid hormones (Vigersky et al., 2006; 
Isidro et al., 2007). 
With this concept the present study was 
performed to ascertain the safe nature of 
lornit and silymarin in CCl4-induced hepa-
totoxic animals with particular reference to 
thyroid functions and tissue lipid peroxida-
tion (LPO), considering laboratory mouse 
as working model. We also investigated the 
alterations in serum glucose and insulin 
levels; aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and alka-
line phosphatase (ALP) activities and in 
endogenous antioxidants such as in the ac-
tivities of superoxide dismutase (SOD), 
catalase (CAT) and in reduced glutathione 
(GSH) content, all being related to thyroid 
functions (Goel et al., 1994; Maiti and Kar, 
1998; Kar and Panda, 2005; Jatwa and Kar, 
2006a, b; Jatwa and Kar, 2007; Jatwa et al., 
2007; Panda and Kar, 2007). As women are 
known to be more prone to thyroid abnor-
malities (Fry, 1993; Bülow et al., 2006), for 
the present investigation only female ani-
mals were considered. 
 
MATERIALS AND METHODS 
Drugs and Chemicals 
The test drugs L-ornithine-L-aspartate 
(lornit®, Sun Pharma Co., India) and sily-
marin (Silybon®, Micro Labs. Co, India) 
were purchased from a registered local 
medical store, while dithiothreitol (DTT), 
CCl4, L-thyroxine (L-T4) and 2-thiobarbi-
turic acid (TBA) were from Sigma Chemi-
cals Co. Ltd. St. Louis, USA. Pyrogallol, 
hydrogen peroxide, diethylene triamine 
penta acetic acid, sodium dodecyl sulphate, 
ethylene diamine tetra acetic acid (EDTA) 
and sulphuric acid were purchased from E. 
Merk Ltd, Mumbai, India. Radioimmunoas-
say (RIA) kits, for the estimation of differ-
ent hormones were obtained from Bhabha 
Atomic Research Centre (BARC), Mumbai, 
India. All other chemicals were of reagent 
grade and purchased from Loba Chemie, 
Mumbai, India.  
Animals 
Colony bred adult Swiss albino female 
mice, weighing 30 ± 2 g, were acclimated 
for a week in a light (14 h light: 10 h dark 
cycle) and temperature (23 ± 2 °C) con-
trolled room with the provision of labora-
tory feed (Gold Mohur feed, Hindustan 
Lever Ltd., Mumbai, India) and water ad 
libitum.  
Experimental design  
Forty-two healthy mice were divided 
into six groups of seven each. Animals of 
group 1 receiving the vehicle, vegetable oil 
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(0.1 ml/animal, p.o.) served as control, 
while those of group 2, 3 and 4 received 
CCl4 (2.0 gm/kg, p.o, mixed with vegetable 
oil at 1:1 ratio) twice a week (Wang et al., 
1997; He et al., 2006; Balderas-Renteria et 
al., 2007) to induce liver damage. After 24 
hours of CCl4 administration animals of 
group 1 and 2 received vehicle, distilled 
water (0.1 ml/animal/day, p.o) and those of 
group 3 and 4 received lornit (200 mg/kg/ 
day, p.o., Maneesh and Jayalekshmi, 2005) 
or silymarin (100mg/kg/day, p.o., Lee et al., 
2007) respectively for 14 days, while ani-
mals of group 5 and 6 were administered 
only with equivalent amount of lornit and 
silymarin respectively. Drug or vehicle ad-
ministration was done by gastric intubation 
method between 1000 and 1100 h of the 
day to avoid circadian variation, if any. 
Animals were maintained as per the 
guidelines laid down by departmental Ethi-
cal Committee for Handling and Mainte-
nance for Experimental Animals and the 
Committee for the Purpose of Control and 
Supervision on Experiments in Animals 
(CPCSEA), Ministry of Environment and 
Forests, Government of India. 
 
Preparation of serum and tissue samples 
On the day of termination (15th day), 
over-night fasted animals were killed after 
exposing them to mild ether anesthesia. 
Blood from each animal was collected and 
serum was isolated for the estimation of 
different biochemical and hormonal pa-
rameters. After exsanguinations, both the 
kidneys and liver were removed, quickly 
freed from blood clots and washed thor-
oughly with phosphate buffered saline 
(PBS, 0.1 M, pH 7.4), weighed and proc-
essed for the estimations of LPO, SOD and 
CAT activities and GSH and protein con-
tents.  
 
Assay of thyroid hormones 
Total circulating T3 and T4 were esti-
mated by RIA in serum samples following 
the protocols provided in the kits as rou-
tinely followed in our laboratory (Jatwa and 
Kar, 2006a, b; Jatwa and Kar, 2007; Jatwa 
et al., 2007; Panda and Kar, 2007). In brief, 
RIA was performed using tris hydroxy-
methyl amino methane buffer (0.14 M, con-
taining 0.1 % gelatin; pH 8.6). The antisera, 
specific hormone standards, radio labeled 
hormones (I125 T4 and I125 T3) and the con-
trol sera were reconstituted with assay 
buffer/double distilled water. The reaction 
mixture comprised of standard/sample, 
buffer, radio labeled hormone and the re-
spective antibody was incubated at 37 °C 
(30 min. for T4 and 45 min. for T3). Incuba-
tion was terminated by the addition of poly-
ethylene glycol. Tubes were then centri-
fuged at 2000 X g for 20 min. After decant-
ing the supernatant, traces of liquid were 
removed with the help of filter paper wicks 
without disturbing the precipitate. Finally 
the tubes were subjected to radioactivity 
counting for one minute (CPM) using an 
I125 gamma counter. A set of quality control 
sera was also used with each assay. 
 
Hormone assay of insulin 
Assay of total serum insulin was also 
done following the protocol provided in 
RIA kit as routinely followed in our labora-
tory (Jatwa and Kar, 2006a; Jatwa and Kar, 
2007; Jatwa et al., 2007). In brief, 200 μl of 
assay buffer and 100 μl of serum sam-
ple/standard were mixed and then 100 μl of 
primary antibodies (anti-porcine guinea pig 
IgG) were added and the mixture was incu-
bated at 4 °C for overnight. Following the 
incubation, 100 μl of I125-labeled insulin 
was added. After 3 hours of incubation at 
room temperature, 100 μl of secondary an-
tibodies (anti-guinea pig-rabbit IgG) were 
added followed by addition of 1 ml poly-
ethylene glycol. After gentle mixing, tubes 
were incubated at room temperature for 
20 min and then centrifuged at 1500 X g for 
20 min at room temperature. After decant-
ing the supernatant, traces of liquid were 
removed with the help of filter paper wicks 
without disturbing the precipitate. Finally 
tubes were subjected to radioactivity count-
ing for one minute (CPM) using an I125 
gamma counter. A set of quality control 
sera of mice was also used with each assay. 
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Study of hepatic 5’DI activity 
For the evaluation of hepatic 5’DI en-
zyme activity, an established method (Kahl 
et al., 1987) was followed as commonly 
used in our laboratory (Maiti and Kar, 
1998; Jatwa and Kar, 2007; Panda and Kar, 
2007). In brief, the liver was homogenized 
in 3 volumes of ice-cold phosphate buffer 
(0.15 M, pH 7.4) containing 5 mM EDTA. 
The homogenate was centrifuged at 2000 X 
g for 30 min at 4 °C, then the supernatant 
was incubated with assay buffer, L-T4 
(4 μM) and DTT for an hour at 37 °C. Fi-
nally the incubation was terminated with 
the addition of absolute ethanol and the es-
timation of T3 was done using RIA. 
 
Estimations of ALT, AST and ALP activities 
For the estimation of ALT and AST ac-
tivities in serum samples, commercially 
available enzymatic kits, based on the reac-
tion of 2, 4 dinitro phenyl hydrazine with 
pyruvate and/or oxaloacetate to yield a 
brown colored complex in alkaline medium 
were used (Reitman and Frankel, 1957). 
Serum ALP activity was evaluated using 
the spectrophotometric method of King 
(1965), as followed earlier in our laboratory 
(Jatwa and Kar, 2006b; Jatwa et al., 2007). 
 
Serum glucose estimation 
Fasting serum glucose concentration 
was estimated by glucose oxidase/per-
oxidase method of Trinder (1969), where 4-
aminoantipyrine and phenol react with glu-
cose to yield a red colored complex (Jatwa 
and Kar, 2007; Panda and Kar, 2007). 
 
Biochemical estimations of LPO and GSH 
content 
For the evaluation of LPO, the liver and 
kidney tissues were homogenized in 10 % 
(w/v) ice-cold phosphate buffered saline 
(0.1M, pH 7.4), centrifuged at 2,000 X g for 
30 min and the supernatant was used for the 
assay (Ohkawa et al., 1979; Jatwa and Kar, 
2006a, b; Jatwa and Kar, 2007; Jatwa et al., 
2007; Panda and Kar, 2007). In brief, LPO 
was determined by the reaction of 2-thio-
barbuturic acid with malondialdehyde 
(MDA), one of the major products formed 
by peroxidation of lipids, in acidic medium. 
Amount of MDA was measured by taking 
the absorbance at 532 nm (extinction coef-
ficient, E =1.56 x105), using a Shimadzu 
UV-1700 spectrophotometer. While tissue 
reduced glutathione content was measured 
by taking the absorbance of the product 
formed by the reaction of Ellman’s reagent 
with GSH at 412 nm (Extinction coeffi-
cient, E= 1.36x104) following the method 
of Ellman (1959), as done earlier in our 
laboratory (Jatwa and Kar, 2007; Jatwa et 
al., 2007).  
 
Estimations of SOD and CAT activities and 
protein content 
The endogenous SOD activity was de-
termined using the pyrogallol autoxidation 
inhibition assay following the protocol of 
Marklund and Marklund (1974). The rate of 
autoxidation was determined by recording 
the increase in the absorption at 420 nm 
(Jatwa and Kar, 2006a, b; Jatwa and Kar, 
2007; Jatwa et al., 2007; Panda and Kar, 
2007). CAT activity was estimated by con-
sidering the method of Aebi (1983), based 
on the estimation of amount of hydrogen 
peroxide decomposed as routinely done in 
our laboratory (Jatwa and Kar, 2006a, b; 
Jatwa et al., 2007; Panda and Kar, 2007). 
Tissue protein estimation was done by the 
routine method of Lowry et al. (1951) using 
bovine serum albumin as standard. 
 
Statistical analysis 
Data are expressed as mean ± S.E.M. 
For statistical evaluation of the data, analy-
sis of variance (ANOVA) and the Student’s 
t-test were used.  
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RESULTS 
Effects on LPO and antioxidants 
Administration of CCl4 to mice on one 
hand increased hepatic and renal LPO 
(Fig. 1), on the other hand it decreased 
GSH, SOD, and CAT activities. While 
treatment with either lornit or silymarin to 
CCl4 intoxicated animals reduced the LPO, 
there was a significant increase in the ac-
tivities of SOD, CAT and GSH. In normal 
animals also both the drugs reduced tissue 
LPO with a significant increase in these 
three antioxidants (Table 1).  
 
Effects on serum thyroid hormones and on 
hepatic 5’DI enzyme activity 
A significant decease in serum T3 con-
centration and hepatic 5’DI enzyme activity 
was observed following CCl4 administra-
tion. However, treatment with either lornit 
or silymarin reversed these abnormalities as 
both drugs increased 5’DI activity and se-
rum T3 concentration (Fig. 2). No signifi-
cant alteration in serum T4 level was no-
ticed. 
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Figure 1: Effects of lornit 
or silymarin on the 
changes in hepatic and 
renal LPO (nM MDA 
formed / mg protein / hr) in 
CCl4-induced hepatotoxic 
and control female mice. 
Each vertical bar repre-
sents the mean ± S.E.M. 
(n=7). ***, P < 0.001; **, P < 
0.01 as compared to the 
respective control values 
and +++, P < 0.001 as com-
pared to the respective 
values of the CCl4-treated 
group. 
Figure 2: Effects of lornit 
or silymarin on the chan-
ges in concentrations of 
serum T3 and T4 (ng/ml) 
and hepatic 5’DI (ng of T3 
generated/mg protein/hr) 
in CCl4-induced hepato-
toxic and normal female 
mice. Each vertical bar 
represents the mean ± 
S.E.M. (n=7). ***, P < 0.001 
as compared to the re-
spective control values 
and +++, P < 0.001 as com-
pared to the respective 
values of the CCl4-treated 
group. 
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Table 1: Effect of Lornit (200 mg/kg/day, p.o.) or Silymarin (100 mg/kg/day, p.o.) administration for 14 
days on the activities of hepatic and renal SOD (U/mg protein) and  CAT (μM H2O2 decomposed/min/ 
mg protein) and GSH content (μM GSH/mg protein) on control and CCl4  (2.0 g/kg, twice a week) 
treated female mice. 
 
 
Parameters   Control      CCl4       CCl4 + Lornit   CCl4 + silymarin     Lornit      silymarin      
 
 
Hepatic  
SOD             2.53           1.05***         3.65+++             3.93+++             3.68***         3.10***  
                     ±0.10         ±0.09           ±0.12               ±0.13              ±0.18          ±0.07  
  
CAT             42.79         27.62***        48.50+++           42.61+++           49.22*          50.64*        
                     ±2.12         ±1.01           ±2.13               ±2.21               ±2.01         ±2.63 
 
GSH             3.50           2.07***         4.23+++                     5.07+++             4.09*            4.72*  
                     ±0.21         ±0.10           ±0.31               ±0.42                ±0.42         ±0.41  
 
Renal  
SOD             4.72            3.36**          5.50+++                    5.21+++             7.10**           8.12*** 
                     ±0.32          ±0.22          ±0.35                ±0.36              ±0.6             ±0.7 
 
CAT             40.31          30.72**        42.61++             43.66++            49.06*          49.05*                
                     ±2.08          ±2.04          ±2.48                ±2.61              ±3.01          ±2.01 
 
GSH             5.73            4.53*            8.80+++                    8.63+++             8.81***         8.13***  
                     ±0.28          ±0.31          ±0.39                ±0.51              ±0.29          ±0.31 
 
 
Data are mean ± S.E.M. (n=7). +++, P < 0.001 and ++ P < 0.01 as compared to the respective values of 
CCl4 treated group. ***, P < 0.001; **, P < 0.01 and *, P < 0.05 as compared to the respective control 
values. 
 
 
Serum ALT, AST and ALP activities and on 
the concentration of insulin and glucose 
CCl4 administration significantly in-
creased serum ALT, AST and ALP activi-
ties as well as insulin and glucose concen-
trations. However, either lornit or silymarin 
administration to CCl4 treated animals re-
versed all these changes bringing down the 
values to nearly normal levels (Table 2). 
 
DISCUSSION 
Results revealed that administration of 
CCl4 to mice increased the LPO in both he-
patic and renal tissues; serum AST, ALT 
and ALP activities; fasting glucose and in-
sulin concentrations, but lowered serum 
level of T3 and hepatic 5’DI activity, indi-
cating a peroxidative, hyperglycemic and 
hypothyroidic conditions. While the CCl4 
induced alterations in most of these parame-
ters including hypothyroidism, hyperinsu-
linemia and increase in hepatic LPO are in 
accordance with the earlier observations 
made by some other workers (Meyer-Alber 
et al., 1992; Goel et al., 1994; Castilla-
Cortazar et al., 1997), practically nothing 
was known in relation to hepatic activity of 
5’DI, the enzyme responsible for major 
amount of T3 production (Ganong, 1995) 
and on renal peroxidative system which 
have been evaluated in the present study. 
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Table 2: Effect of Lornit (200 mg/kg/day, p.o.) or Silymarin (100 mg/kg/day, p.o.) administration for 14 
days on the activities of serum AST (U/l); ALT (U/l) and ALP (KA units/l) and insulin (IU/l) and glucose 
(mg/dl) concentrations in normal and CCl4 (2.0 g/kg, twice a week) treated female mice. 
 
 
Parameters   Control         CCl4      CCl4 + Lornit   CCl4 + Silymarin   Lornit    Silymarin                
 
 
ALT                  38.25         120.2***        44.0+++               45.12+++          40.2           41.0 
                        ±1.57          ±5.11          ±2.03            ±2.40              ±2.11         ±2.03 
 
AST                 13.80          30.8***         15.0+++          15.80+++          14.80         15.0    
                        ±0.61          ±1.50          ±0.54            ±0.61              ±0.80         ±0.94 
 
ALP                 15.69          19.74*          10.18+++       11.07+++          12.94         16.46    
                 ±0.98          ±1.21           ±0.81           ±0.82               ±0.87        ±0.81 
 
Insulin              21.0            42.0***          20.0+++             18.75+++           20.33        20.25 
                        ±0.93           ±1.2            ±0.89           ±0.80               ±1.2          ±0.79 
  
Glucose           84.84          118.34***      90.34+++          93.75+++           80.83        79.83 
                                  ±2.89           ±4.03          ±2.31           ±2.85               ±3.89        ±4.89 
 
 
Data are mean ± S.E.M. (n=7). +++, P < 0.001 as compared to the respective values of CCl4 treated 
group. ***; P < 0.001 and *, P < 0.05 as compared to the respective control values. 
 
 
While carbon tetrachloride induced in-
crease in hepatic LPO, observed in the pre-
sent study indicating a condition of liver 
damage is well documented in experimental 
models (Weber et al., 2003; Yamazaki et 
al., 2005; He et al., 2006; Lee et al., 2007; 
Tu et al., 2007), the additional findings on 
the increased levels of serum ALT, AST 
and ALP activities in CCl4 treated group 
further corroborated its hepatotoxic nature. 
This could be an outcome of loss of mem-
brane integrity and increased oxidative 
stress as suggested earlier (He et al., 2006; 
Lee et al., 2007). It is well understood that 
CCl4 is activated by phase 1-cytochrome 
P450 enzymes to trichloromethyl (CCl3) 
free radicals (Weber et al., 2003; Aleksunes 
et al., 2005) which initiate a chain of reac-
tions by abstracting hydrogen ion from 
nearby polyunsaturated fatty acids (PUFA) 
and result in increased production of thio-
barbituric acid reactive substances 
(TBARS), the major products of lipid per-
oxidation (He et al., 2006). In fact, peroxi-
dation of lipids, particularly those contain-
ing PUFA can dramatically change the 
properties of biological membranes and 
some times result in severe cell damage 
(Weber et al., 2003; Aleksunes et al., 2005). 
Therefore, in the present investigation, ele-
vation in hepatic LPO could be an outcome 
of CCl4-induced cellular damage. It could 
also be due to the decreased activities of 
endogenous antioxidants such as SOD, 
CAT and GSH (Yamazaki et al., 2005; He 
et al., 2006; Lee et al., 2007) as all these 
have an inverse relationship with LPO. 
The interesting findings are that the ad-
ministration of either of the test drugs to 
CCl4 treated animals reversed most of these 
adverse effects including CCl4 induced hy-
pothyroidism and oxidative stress. To the 
best of our knowledge, for the first time we 
report the impact of lornit and silymarin 
therapy on thyroid metabolism of an animal 
model. Therefore, our findings can be com-
pared to that of some recent clinical reports 
suggesting an altered thyroid hormone me-
tabolism due to chronic medication with 
some other drugs (Vigersky et al., 2006; 
Isidro et al., 2007). In fact, lornit admini-
stration stimulated the hepatic 5’DI activity 
and the serum T3 level, but reduced the tis-
sue LPO and serum glucose level. While 
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silymarin was earlier known to be effective 
against chemically induced tissue LPO, hy-
perinsulinemia and hyperglycemia (Soto et 
al., 2004; Huseini et al., 2006), practically 
nothing was reported on the impact of lornit 
on these aspects. Interestingly, simultane-
ous administration of either lornit or sily-
marin to these animals reversed the CCl4-
induced hepatic LPO. These observations 
are somewhat similar to the earlier reports 
which too indicated the amelioration of 
chemical-induced tissue LPO and oxidative 
stress following the administration of test 
hepatoprotective drugs (Maneesh and 
Jayalekshmi, 2005; Mansour et al., 2006; 
Poo et al., 2006; Lee et al., 2007; Upadhyay 
et al., 2007). The tissue protective nature of 
both the evaluated drugs was further sup-
ported by the increased activities of en-
dogenous antioxidants such as SOD, CAT 
and GSH, as also observed by some other 
workers (Mansour et al., 2006; Balderas-
Renteria et al., 2007). However, lornit ex-
hibited a better efficacy in the reduction of 
CCl4-induced hepatic LPO (60.13 %) than 
that of silymarin (55.58 %) and some what 
similar inhibition was observed when the 
tested dugs were administered to normal 
healthy animals (62.12 % and 36.86 % for 
lornit and silymarin, respectively). 
Observations on fasting serum glucose 
following CCl4 administration indicated a 
hyperglycemic condition as reported by ear-
lier workers (Meyer-Alber et al., 1992; Cas-
tilla-Cortazar et al., 1997). However, CCl4 
also elevated serum insulin concentration, 
indicating a condition of insulin resistance. 
This observed elevation in fasting serum 
glucose (39.48 %) could be an outcome of 
CCl4-induced decrease in GLUT2 mediated 
absorption of circulating sugar as suggested 
earlier (Meyer-Alber et al., 1992; Castilla-
Cortazar et al., 1997). Interestingly, simul-
taneous administration of either lornit or 
silymarin and CCl4 reversed these abnor-
malities suggesting the potency of both the 
test drugs, in the amelioration of CCl4-
induced hyperglycemia and insulin resis-
tance. Of course, the percent decrease of 
fasting serum glucose in case of lornit was 
little higher (23.66) as compared to sily-
marin (19.08) suggesting a relatively better 
efficacy of the former one over the latter 
drug in ameliorating hyperglycemia. These 
favorable effects of both the test drugs on 
glucose metabolism could be the outcome 
of a decrease in oxidative stress (discussed 
latter) on hepatic tissues, which might have 
facilitated the glycogen synthesis and re-
duced insulin resistance (Szkudelski, 2001). 
For the first time an increase in renal 
LPO (23.62 %) following CCl4 administra-
tion was also observed, which was nearly 
normalized by the administration of lornit 
or silymarin, suggesting the beneficial role 
of the test drugs with respect to renal func-
tions, too. This kidney protective effect 
could either be the direct free radical scav-
enging activity of two drugs or could indi-
rectly be the result of an elevation in the 
levels of endogenous antioxidants such as 
SOD, CAT and GSH, those were reduced 
following CCl4 treatment.  
With respect to the changes in the level 
of thyroid hormones, there was a decrease 
in T3 concentration following CCl4 admini-
stration as reported by earlier workers (Goel 
et al., 1994), which was reversed on simul-
taneous administration with either lornit or 
silymarin. It is quite possible that this CCl4 
induced decrease in thyroid function is an 
outcome of CCl4-induced hepatotoxicity, as 
out of the two major circulating thyroid 
hormones, T4 is synthesized only in thyroid 
gland, while the major amount of T3 (85-
90 %) is produced by the mono-deiodina-
tion of T4, primarily in hepatic and renal 
tissues with the help of enzyme 5’DI 
(Ganong, 2005). This fact was further sup-
ported by the decreased hepatic 5’DI en-
zyme activity (47.22 %) in the animals of 
CCl4 treated group, suggesting that chronic 
administration of hepatotoxic chemicals 
may reduce hepatic 5’DI enzyme activity 
(Maiti and Kar, 1998). On the other hand, 
lornit or silymarin administration to CCl4-
induced hepatotoxic animals resulted in the 
reversal in the serum T3 concentration. This 
was further supported by increased 5’DI 
enzyme activity in hepatic tissues (94.73 % 
and 100 % for lornit and silymarin, respec-
tively). As in present study, following lornit 
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or silymarin administration only the level of 
T3 and 5’DI activity were increased, it 
seems that the test drugs regulate thyroid 
function only at the level of peripheral con-
version of T4 to T3. The possible mecha-
nism could be that the tissue protective ef-
fects of both the test drugs might have re-
duced the oxidative stress and increased the 
liver function indicating 5’DI activity and 
subsequently the T3, as suggested earlier 
(Maiti and Kar, 1998; Kar and Panda, 2005; 
Jatwa and Kar, 2007).  
In summary, both lornit and silymarin 
appear to have the potential to protect he-
patic and renal toxicity induced by xenobi-
otics, with an additional benefit of amelio-
rating hyperglycemia and thyroid dysfunc-
tion. It is further suggested that both the test 
drugs may prove to be safe for chronic 
medication with particular reference to an-
tioxidant defense system and thyroid func-
tions. However, lornit appears to be more 
potent than silymarin in regulating the tis-
sue toxicity, both in liver and kidney. 
 
Acknowledgements: Financial support 
from the Council of Scientific and Indus-
trial Research (CSIR), New Delhi, India for 
a Senior Research Fellowship (SRF) to R. 
Jatwa is gratefully acknowledged. We also 
thank Dr. S. Panda, Mr. H.S. Parmar and 
Ms. Y. Dixit for some help. 
 
REFERENCES 
Aebi HE. Catalase. In: Bergmeyer HU (ed). 
Methods in enzymatic analysis (pp 276-86). 
New York: Academic Press, 1983. 
Aleksunes LM, Slitt AM, Cherrington NJ, 
Thiodeau MS, Klaassen CD, Manautou JE. 
Differential expression of mouse hepatic 
transporter genes in response to acetamino-
phen and carbon tetrachloride. Toxicol Sci 
2005;83:44-52. 
Balderas-Renteria I, Camacho-Corona Mdel 
R, Carranza-Rosales P, Lozano-Garza HG, 
Castillo-Nava D, Alvarez-Mendoza. Hepa-
toprotective effect of Leucophyllum frutes-
cens on Wistar albino rats intoxicated with 
carbon tetrachloride. Ann Hepatol 2007;6: 
251-4. 
Bülow Pedersen I, Laurberg P, Knudsen N, 
Jørgensen T, Perrild H, Ovesen L 
Rasmussen LB. Lack of association be-
tween thyroid autoantibodies and parity in a 
population study argues against microchi-
merism as a trigger of thyroid autoimmu-
nity. Eur J Endocrinol 2006;154:39-45. 
Castilla-Cortazar I, Garcia M, Muguerza B, 
Quiroga J, Perez R, Santidrian S, Prieto J. 
Hepatoprotective effects of insulin-like 
growth factor I in rats with carbon tetra-
chloride-induced cirrhosis. Gastroentero-
logy 1997;113:1682-91. 
Clawson GA. Mechanisms of carbon tetra-
chloride hepatotoxicity. Pathol Immunopa-
thol Res 1989;8:104-12. 
Delcker A, Turowski B, Mihm U, Raab P, 
Rusch O, Pilatus U, Zeuzem S, Zanella FE. 
Proton MR spectroscopy of neurometabo-
lites in hepatic encephalopathy during L-
ornithine-L-aspartate treatment--results of a 
pilot study. Metab Brain Dis 2002;17:103-
11. 
Ellman GL. Tissue sulfhydryl groups. Arch 
Biochem Biophy 1959;82:70-7. 
Fry C. Thyroid related diseases and their 
treatment. Eastern Pharm 1993;27-9. 
Ganong WF. Review of medical physiol-
ogy. New York: Appleton & Lange, 2005. 
Gebhardt R, Beckers G, Gaunitz F, Haupt 
W, Jonitza D, Klein S, Scheja L. Treatment 
of cirrhotic rats with L-ornithine-L-aspar-
tate enhances urea synthesis and lowers se-
rum ammonia levels. J Pharmacol Exp Ther 
1997;283:1-6. 
EXCLI Journal 2008;7:139-150 – ISSN 1611-2156 
Received: May 08, 2008, accepted: May 15, 2008, published: May 20, 2008 
 
148 
Goel A, Dhawan D, Kheruka S. Evaluation 
of zinc in the regulation of serum T3 and 
T4 levels and hepatic functions in carbon 
tetrachloride-intoxicated rats. Biol Trace 
Elem Res 1994;41:59-68. 
He SX, Luo JY, Wang YP, Wang Yl, Fu H, 
Xu JL, Zhao G, Liu EQ. Effects of extract 
from Ginkgo biloba on carbon tetrachlo-
ride-induced liver injury in rats. World J 
Gastroenterol 2006;28:3924-8. 
Huseini HF, Larijani B, Heshmat R, 
Fakhrzadeh H, Radjabipour B, Toliat T, 
Raza M. The efficacy of Silybum marianum 
(L.) Gaertn. (silymarin) in the treatment of 
type II diabetes: a randomized, double-
blind, placebo-controlled, clinical trial. 
Phytother Res 2006;20:1036-9. 
Isidro ML, Penin MA, Nemina R, Cordido 
F. Metformin reduces thyrotropin levels in 
obese, diabetic women with primary hypo-
thyroidism on thyroxine replacement ther-
apy. Endocrine 2007; 32:79-82. 
Jain A, Soni M, Deb L, Jain A, Rout SP, 
Gupta VB, Krishna KL. Antioxidant and 
hepatoprotective activity of ethanolic and 
aqueous extracts of Momordica dioica 
Roxb leaves. J Ethnopharmacol 2008;115: 
61-6. 
Jatwa R, Kar A. Antihyperglycemic and 
antiperoxidative roles of acarbose in type 2 
diabetes mellitus are possibly mediated 
through changes in thyroid function. Clin 
Exp Pharm Physiol 2006a;33:1104-6. 
Jatwa R, Kar A. Cardio-protective role of 
terazosin is possibly mediated through al-
teration in thyroid function. Eur J Pharma-
col 2006b;551:87-91. 
Jatwa R, Kar A. Positive influence of 
centchroman on cardiovascular system and 
tissue lipid peroxidation in rats. Contra-
eption 2007;76:408-12. 
Jatwa R, Parmar HS, Panda S, Kar A. Ame-
lioration of corticosteroid-induced type 2 
diabetes mellitus by rosiglitazone is possi-
bly mediated through stimulation of thyroid 
function and inhibition of tissue lipid per-
oxidation in mice. Basic Clin Pharmacol 
Toxicol 2007;101:177-80. 
Kahl S, Capuco AV, Bitman J. Serum con-
centrations of thyroid hormones and extra-
thyroidal thyroxine-5'-monodeiodinase ac-
tivity during lactation in the rat. Proc Soc 
Exp Biol Med 1987;184:144-50. 
Kar A, Panda S. Plant extracts in the regu-
lation of hypothyroidism In: Sharma SK, 
Govil JN, Singh VK (eds). Recent pogress 
in mdicinal pants (pp 419-26). Texas: 
Studium Pr., 2005. 
King J. Practical clinical enzymology. Lon-
don: Nostrand Company Ltd., 1965.  
Kircheis G, Wettstein M, Dahl S, 
Häussinger D. Clinical efficacy of L-
ornithine-L-aspartate in the management of 
hepatic encephalopathy. Metab Brain Dis 
2002;17:453-62. 
Lee HS, Keum KY, Ku SK. Effects of 
Picrorrhiza rhizoma water extracts on the 
subacute liver damages induced by carbon 
tetrachloride. J Med Food 2007;10:110-7. 
Lee WM. Acute liver failure in the United 
States. Semin Liver Dis 2003;23:217-26. 
Lowry OH, Rosebrough NJ, Farr AL, Ran-
dall RJ. Protein measurement with the Fo-
lin-phenol reagent. J Biol Chem 1951;193: 
265-75. 
 
Maiti PK, Kar A. Is triiodothyronine capa-
ble of ameliorating pyrethroid-induced thy-
roid dysfunction and lipid peroxidation? J 
Appl Toxicol 1998;18:125-8. 
EXCLI Journal 2008;7:139-150 – ISSN 1611-2156 
Received: May 08, 2008, accepted: May 15, 2008, published: May 20, 2008 
 
149 
Maneesh M, Jayalekshmi H. Effect of 
ascorbic acid, alpha-tocopherol, lecithin and 
L-ornithine-L-aspartate on ethanol induced 
hypoproteinemia and hyperlipidemia in 
rats. Ind J Physiol Pharmacol 2005;49:422-
6. 
Mansour HH, Hafez HF, Fahmy NM. Sily-
marin modulates Cisplatin-induced oxida-
tive stress and hepatotoxicity in rats. J Bio-
chem Mol Biol 2006;39:656-61. 
Marklund S, Marklund G. Involvement of 
superoxide anion radical in the autoxidation 
of pyrogallol: a convenient assay for super-
oxide dismutase. Eur J Biochem 1974;47: 
469-74. 
Meyer-Alber A, Hartmann H, Sumpel F, 
Creutzfeldt W. Mechanism of insulin resis-
tance in CCl4-induced cirrhosis of rats. 
Gastroenterology 1992;102:223-9. 
Ohkawa H, Ohishi N, Yagi K. Assays of 
lipid peroxides in animal tissues by thio-
barbituric acid reaction. Anal Biochem 
1979;95:351-8. 
Panda S, Kar A. Annona squamosa seed 
extract in the regulation of hyperthyroidism 
and lipid-peroxidation in mice: Possible 
involvement of quercetin. Phytomedicine 
2007;14:799-805. 
Paquet KJ, Kamphausen U. The carbon-
tetrachloride-hepatotoxicity as a model of 
liver damage. First report Long-time bio-
chemical changes. Acta Hepatogastro-
enterol 1975;22:84–8. 
Perez Tamayo R. Is cirrhosis of the liver 
experimentally produced by CCl4 and ade-
quate model of human cirrhosis? Hepatol-
ogy 1983;3:112–20.  
Poo JL, Gongora J, Sanchez-Avila F, Agui-
lar-Castillo S, Garcia-Ramos G, Fernandez-
Zertuche M, Rodríguez-Fragoso L, Uribe 
M. Efficacy of oral L-ornithine-L-aspartate 
in cirrhotic patients with hyperammonemic 
hepatic encephalopathy. Results of a ran-
domized, lactulose-controlled study. Ann 
Hepatol 2006;5:281-8. 
Reitman S, Frankel S. A colorimetric 
method for the determination of serum glu-
tamic oxalacetic and glutamic pyruvic 
transaminases. Am J Clin Pathol 1957;28: 
56-63. 
Rose C, Michalak A, Rao K, Quack G, 
Kircheis G, Butterworth R. L-ornithine-L-
aspartate lowers plasma and cerebrospinal 
fluid ammonia and prevents brain edema in 
rats with acute liver failure. Hepatology 
1999;30:636-40. 
Soto C, Mena R, Luna J, Cerbon M, Larri-
eta F, Vital P, Uría E, Sánchez M, Recoba 
R, Barrón H, Favari L, Lara A. Silymarin 
induces recovery of pancreatic function af-
ter alloxan damage in rats. Life Sci 
2004;75:2167-80. 
Szkudelski T. The mechanism of alloxan 
and streptozotocin action in B cells of the 
rat pancreas. Physiol Res 2001;50:536-46. 
Trinder P. Determination of blood glucose 
using an oxidase-peroxidase system with a 
non-carcinogenic chromogen. J Clin Pathol 
1969;22:158-61. 
Tu CT, Guo JS, Wang M, Wang JY. Anti-
fibrotic activity of rofecoxib in vivo is as-
sociated with reduced portal hypertension 
in rats with carbon tetrachloride-induced 
liver injury. J Gastroenterol Hepatol 2007; 
22:877-84. 
Upadhyay G, Kumar A, Singh MP. Effect 
of silymarin on pyrogallol and rifampicin-
induced hepatotoxicity in mouse. Eur J 
Pharmacol 2007;565:190-201. 
EXCLI Journal 2008;7:139-150 – ISSN 1611-2156 
Received: May 08, 2008, accepted: May 15, 2008, published: May 20, 2008 
 
150 
Vigersky RA, Filmore-Nassar A, Glass AR. 
Thyrotropin suppression by metformin. J 
Clin Endocrinol Metab 2006;91:225-7. 
Vogels BA, Karlsen OT, Mass MA, Boveé 
WM, Chamuleau RA. L-ornithine vs. L-
ornithine-L-aspartate as a treatment for hy-
perammonemia-induced encephalopathy in 
rats. J Hepatol 1997;26:174-82. 
Wang PY, Kaneko T, Tsukada H, Nakano 
M, Nakajima T, Sato A. Time courses of 
hepatic injuries induced by chloroform and 
by carbon tetrachloride: comparison of  
biochemical and histopathological changes. 
Arch Toxicol 1997;71:638-45. 
Weber LW, Boll M, Stampfl A. Hepatotox-
icity and mechanism of action of haloal-
kanes: carbon tetrachloride as a toxicologi-
cal model. Crit Rev Toxicol 2003;33:105-
36. 
Yamazaki Y, Kakizaki S, Horiguchi N, 
Takagi H, Mori M, Negishi M. Role of nu-
clear receptor CAR in carbon tetrachloride-
induced hepatotoxicity. World J Gastroen-
terol 2005;11:5966-72. 
 
 
